This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chauty, A.
Right arrow Articles by Grosset, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chauty, A.
Right arrow Articles by Grosset, J.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, November 2007, p. 4029-4035, Vol. 51, No. 11
0066-4804/07/$08.00+0     doi:10.1128/AAC.00175-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Promising Clinical Efficacy of Streptomycin-Rifampin Combination for Treatment of Buruli Ulcer (Mycobacterium ulcerans Disease){triangledown}

Annick Chauty,1 Marie-Françoise Ardant,1 Ambroise Adeye,1 Hélène Euverte,1 Augustin Guédénon,3 Christian Johnson,2 Jacques Aubry,4 Eric Nuermberger,5 and Jacques Grosset5*

Centre de Dépistage et de Traitement de l'ulcère de Buruli, Pobè, Bénin,1 Buruli Ulcer Control Programme, Cotonou, Bénin,2 Fondation Raoul Follereau, Paris, France,3 University Nantes, Faculty of Pharmacy, F-44093, Inserm, U601, Nantes, France,4 Johns Hopkins University School of Medicine, Center for Tuberculosis Research, Baltimore, Maryland5

Received 6 February 2007/ Returned for modification 23 March 2007/ Accepted 16 May 2007

According to recommendations of the 6th WHO Advisory Committee on Buruli ulcer, directly observed treatment with the combination of rifampin and streptomycin, administered daily for 8 weeks, was recommended to 310 patients diagnosed with Buruli ulcer in Pobè, Bénin. Among the 224 (72%) eligible patients for whom treatment was initiated, 215 (96%) were categorized as treatment successes, and 9, including 1 death and 8 losses to follow-up, were treatment failures. Of the 215 successfully treated patients, 102 (47%) were treated exclusively with antibiotics and 113 (53%) were treated with antibiotics plus surgical excision and skin grafting. The size of lesions at treatment initiation was the major factor associated with surgical intervention: 73% of patients with lesions of >15 cm in diameter underwent surgery, whereas only 17% of patients with lesions of <5 cm had surgery. No patient discontinued therapy for side effects from the antibiotic treatment. One year after stopping treatment, 208 of the 215 patients were actively retrieved to assess the long-term therapeutic results: 3 (1.44%) of the 208 retrieved patients had recurrence of Mycobacterium ulcerans disease, 2 among the 107 patients treated only with antibiotics and 1 among the 108 patients treated with antibiotics plus surgery. We conclude that the WHO-recommended streptomycin-rifampin combination is highly efficacious for treating M. ulcerans disease. Chemotherapy alone was successful in achieving cure in 47% of cases and was particularly effective against ulcers of less than 5 cm in diameter.

* Corresponding author. Mailing address: Center for Tuberculosis Research, Johns Hopkins University School of Medicine, 1550 Orleans Street, Baltimore, MD 21231-1001. Phone: (410) 502-8234. Fax: (410) 614-8173. E-mail: jgrosse4{at}jhmi.edu

{triangledown} Published ahead of print on 25 May 2007.

Antimicrobial Agents and Chemotherapy, November 2007, p. 4029-4035, Vol. 51, No. 11
0066-4804/07/$08.00+0     doi:10.1128/AAC.00175-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Barogui, Y., Johnson, R. C., van der Werf, T. S., Sopoh, G., Dossou, A., Dijkstra, P. U., Stienstra, Y. (2009). Functional Limitations after Surgical or Antibiotic Treatment for Buruli Ulcer in Benin. Am J Trop Med Hyg 81: 82-87 [Abstract] [Full Text]  
  • Ji, B., Chauffour, A., Aubry, A., Robert, J., Ibrahim, M., Jarlier, V. (2009). Impacts of Dosing Frequency of the Combination Rifampin-Streptomycin on Its Bactericidal and Sterilizing Activities against Mycobacterium ulcerans in Mice. Antimicrob. Agents Chemother. 53: 2955-2959 [Abstract] [Full Text]  
  • Eddyani, M., Fraga, A. G., Schmitt, F., Uwizeye, C., Fissette, K., Johnson, C., Aguiar, J., Sopoh, G., Barogui, Y., Meyers, W. M., Pedrosa, J., Portaels, F. (2009). Fine-Needle Aspiration, an Efficient Sampling Technique for Bacteriological Diagnosis of Nonulcerative Buruli Ulcer. J. Clin. Microbiol. 47: 1700-1704 [Abstract] [Full Text]  
  • Phillips, R. O., Sarfo, F. S., Osei-Sarpong, F., Boateng, A., Tetteh, I., Lartey, A., Adentwe, E., Opare, W., Asiedu, K. B., Wansbrough-Jones, M. (2009). Sensitivity of PCR Targeting Mycobacterium ulcerans by Use of Fine-Needle Aspirates for Diagnosis of Buruli Ulcer. J. Clin. Microbiol. 47: 924-926 [Abstract] [Full Text]  
  • Sarfo, F. S., Phillips, R. O., Ampadu, E., Sarpong, F., Adentwe, E., Wansbrough-Jones, M. (2009). Dynamics of the Cytokine Response to Mycobacterium ulcerans during Antibiotic Treatment for M. ulcerans Disease (Buruli Ulcer) in Humans. CVI 16: 61-65 [Abstract] [Full Text]  
  • Ji, B., Chauffour, A., Robert, J., Jarlier, V. (2008). Bactericidal and Sterilizing Activities of Several Orally Administered Combined Regimens against Mycobacterium ulcerans in Mice. Antimicrob. Agents Chemother. 52: 1912-1916 [Abstract] [Full Text]  
  • Ji, B., Chauffour, A., Robert, J., Lefrancois, S., Jarlier, V. (2007). Orally Administered Combined Regimens for Treatment of Mycobacterium ulcerans Infection in Mice. Antimicrob. Agents Chemother. 51: 3737-3739 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»